Low-risk persistent gestational trophoblastic disease: Outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000

Journal of Clinical Oncology

Volumn 20, Issue 7, 2002, Pages 1838-1844

  McNeish, I A ^a   Strickland, S ^a   Holden, L ^a   Rustin, G J S ^a   Foskett, M ^a   Seckl, M J ^a   Newlands, E S ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; VINCRISTINE;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG INDUCED DISEASE; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL RATE; TROPHOBLASTIC DISEASE; UNITED KINGDOM;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHORIONIC GONADOTROPIN; CLINICAL PROTOCOLS; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; METHOTREXATE; PREGNANCY; RISK; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TROPHOBLASTIC NEOPLASMS; UTERINE NEOPLASMS; VINCRISTINE;

EID: 0036534303     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.166     Document Type: Article

References (20)

1. The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumors (GTT)
2. Developments in chemotherapy for medium- and high-risk patients with gestational trophoblastic tumours (1979-1984)
3. Results with the EMA/CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) regimen in high-risk gestational trophoblastic tumors, 1979 to 1989
4. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors
5. Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years
6. Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Heath Organization for Trophoblastic Neoplasia: Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society
7. A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease
8. EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients
9. Presentation and management of persistent gestational trophoblastic disease and gestational trophoblastic tumors in the USA
10. Gestational trophoblastic disease: Does central nervous system chemoprophylaxis have a role?
11. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors
12. Persistent gestational trophoblastic disease: Results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease
13. Correlation between clinical staging (FIGO) and prognostic groups with gestational trophoblastic disease
14. 5-Day methotrexate for women with metastatic gestational trophoblastic disease
15. Remission rates and significance of prognostic factors in gestational trophoblastic tumors
16. Metastatic gestational trophoblastic disease: A comparison of prognostic classification systems
17. Metastatic gestational trophoblastic disease: Experience at the New England Trophoblastic Disease Center from 1965 to 1985
18. Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease
19. Adjuvant hysterectomy in low-risk gestational trophoblastic disease
20. Methotrexate infusion in low-risk gestational trophoblastic disease